Recent News
Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.Read Article
Best of 2024: Efficacy of Biologics in Patients with Chronic Kidney Disease
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.
Read Article
How do you manage skin in Sscl?
-RNA pol III + high risk for skin progression.
-Limited+ low risk + stable Sscl no need for immunesuppresors.
-Look for EF in pts with generalized morphea.
-Ttnt of skin depending on other organ involvements.
-If no Raynaud’s/hands spared think of… https://t.co/DZzhShKzS8 https://t.co/J9Qg1Lk2Wl
Dr. John Cush @RheumNow ( View Tweet)
#ACR24 Year in Review:
💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨)
💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?)
💡 High risk of CV events within 30 days of gout… https://t.co/g3egOpCYNr https://t.co/KMiOEP7pSg
Dr. John Cush @RheumNow ( View Tweet)
🔍 Vaccine immunogenicity with JAKi treatment
Watch Dr. Kevin Winthrop present long-term immunogenicity of an adjuvant recombinant zoster vaccine in patients aged ≥50 years with RA receiving a JAKi. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/xh2X6CO9P5 https://t.co/bhcQKRLR2d
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: Consensus Statements on Vitamin D
https://t.co/K11CekojNy https://t.co/LTYLrYeqFD
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: Inadequate Zoster Vaccination in Immunocompromised Patients
https://t.co/P2S6byNmgI https://t.co/owVSpCRL89
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: Pain Reduction with Methotrexate in Knee Osteoarthritis
https://t.co/1zG2tWQk1f https://t.co/WvTkZ3q2IK
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.
Read Article
Best of 2024: Consensus Statements on Vitamin D
The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation. Interestingly, optimal levels of 25-hydroxy vitamin D (25(OH)D) are still being debated.
Read Article
Sarcoidosis is biopsy supported not proven”
-Dx is clinical with broad ddx.
-Assess organ involvement in all pts.
-Whole body PET can help assess disease activity (not in CNS disease)
-MR brain with pituitary cuts helpful in CNS sarcoid.
#ACR24 @ACRheum @RheumNow… https://t.co/Ka1cHtFOqj
Dr. John Cush @RheumNow ( View Tweet)
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease:
➡️ A. Ogdie: Preventing PsA
➡️ A. Kavanaugh: Biologic Therapies
➡️ K. Gordon: Head-to-Head Studies
Register now!
https://t.co/9qnqtpkwpT https://t.co/95TGS56vyA
Links:
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease
https://t.co/Sd3H5Tzhtf https://t.co/guXzL5bc6R
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: Analgesic Prescribing in Patients with Inflammatory Arthritis
https://t.co/iQrBVzWaI8 https://t.co/Rx86Q57oEZ
Dr. John Cush @RheumNow ( View Tweet)
Bah Humbug Vitamin D (12.20.2024)
https://t.co/Mjuk6buRsX https://t.co/aX8cetkbWc
Dr. John Cush @RheumNow ( View Tweet)
Best of 2024: Inadequate Zoster Vaccination in Immunocompromised Patients
A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.
Read Article
Best of 2024: Pain Reduction with Methotrexate in Knee Osteoarthritis
The Annals of Internal Medicine reports that oral, low dose, weekly methotrexate significantly reduced knee osteoarthritis pain, stiffness, and function in a randomized controlled trial.
Read Article
If high +ANA and NO #rheumatic #disease
LOOK 👀 at #LIVER
#Autoimmune #hepatitis
And
#alcoholic #liver #dx
#ACRBest #ACR24 @rheumnow abst#0627 https://t.co/0bwfgNnB0e
Links:
Dr. John Cush @RheumNow ( View Tweet)
To Behcet’s or not to Behcet’s?
-Aphtous ulcers have unique features(broad ddx)
-Oral+Genital ulcers=CAP not necessary BD.
-Pathergy test ⬆️specific and not limited to skin!
-Pulmonary arterial aneurysms=almost pathognomonic.
-Do not get confused by HLAs. #ACR24 @RheumNow… https://t.co/3nWgILNVYw
Dr. John Cush @RheumNow ( View Tweet)
A Fibroblast Renaissance
Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/GQXWkqMkIW https://t.co/W6UXT4HCeg
Dr. John Cush @RheumNow ( View Tweet)
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated.
https://t.co/8wvSy8555Z https://t.co/vaGt1AylBr
Dr. John Cush @RheumNow ( View Tweet)
From the blog
How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis?
Podcasts
Bah Humbug Vitamin D (12.20.2024)-
54K Peptic Ulcers Annually (12.13.2024)
-
Don’t Buy Guitars (12.6.2024)
ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
Poster Hall
